Archives
-
BAPTA-AM: Evidence, Scope and Limitations
2026-10-09
A source-grounded overview of how BAPTA-AM is interpreted as an intracellular calcium perturbation tool, what the supplied cardiac study actually demonstrates, and where evidence is insufficient for claims about apoptosis, arrhythmia or neuroprotection.
-
ROS-Responsive LNPs for Mutant RAS mRNA Delivery
2026-10-08
Cai and colleagues developed a library of thioketal-containing, ROS-degradable lipids and identified BAmP-TK-12 as a candidate for preferential mRNA delivery to tumor cells. The study further used mRNA encoding the RAS protease DUF5 to show proof-of-concept suppression of mutant RAS signaling in cellular and animal tumor models, while leaving important questions about selectivity, safety, and translation unresolved.
-
S. eriocheiris Entry into Drosophila S2 Cells
2026-10-08
Wei and colleagues established a Drosophila Schneider 2 cell model showing that Spiroplasma eriocheiris can invade insect-derived cells, increase intracellularly, and induce substantial cellular injury. Pharmacological and cytoskeletal perturbation data support roles for clathrin-mediated endocytosis, macropinocytosis, actin filaments, and microtubules, while also highlighting the limits of inhibitor-based pathway assignment.
-
EZ Cap™ Cre mRNA and Precision Delivery
2026-10-07
A translational perspective on how modified Cre recombinase mRNA, delivery selectivity, and rigorous evidence frameworks can shape the next generation of gene-editing and functional genomics research.
-
BRD4770 and G9a: Evidence in Cancer Research
2026-10-07
BRD4770 is presented as a G9a histone methyltransferase inhibitor for studying epigenetic regulation, while available breast cancer evidence concerns a different upstream co-targeting strategy. This overview separates supplier-reported properties from published findings and explains the limits of applying BRD4–RAC1 results to direct G9a inhibition.
-
Cy3 RNA Labeling Kit: From Probe to Evidence
2026-10-06
The Cy3 RNA labeling kit can do more than generate a bright probe: it can help separate RNA localization, delivery, and functional expression. This article connects fluorescent readouts with the ROS-responsive mRNA delivery findings reported by Cai and colleagues while defining key evidence limits.
-
Chlorpromazine and Hepatic Nanoparticle Interpretation
2026-10-06
Chlorpromazine offers a useful pharmacological lens for separating receptor-mediated effects from material-driven behavior in hepatic nanoparticle research. This evidence-focused analysis explains what the 2026 ACS Nano study established, where chlorpromazine hydrochloride may inform interpretation, and which conclusions remain unsupported.
-
How KRAS Phase Separation Drives Colon Tumor Growth
2026-10-05
Wang et al. identify farnesylation at KRAS C185 as a driver of cytoplasmic condensate formation, linking KRAS processing, membrane localization, and colon tumor growth. The study also reports that disrupting this condensate-associated mechanism with selected statins can improve the response to KRAS G12C inhibition, although the findings remain preclinical.
-
Chlorpromazine Research Through a Liver-Cell Lens
2026-10-05
Chlorpromazine research is usually framed through dopamine receptor signaling, schizophrenia research, or antiemetic pharmacology. This article adds a translational perspective by examining how cell-specific nanoparticle disposition can shape the interpretation of future chlorpromazine delivery studies.
-
Tropisetron Hydrochloride: Beyond 5-HT3 Blockade
2026-10-04
Tropisetron Hydrochloride offers a useful lens for connecting 5-HT3 receptor pharmacology, α7-nicotinic receptor signaling, and renal organic-cation transport. This article interprets the available transporter evidence, clarifies what is established versus inferred, and outlines a translational framework without treating in vitro findings as clinical conclusions.
-
Rice 5hmC and Drought Response: Study Insights
2026-10-03
A 2025 rice study combined single-base 5hmC profiling with methylation and transcriptome analyses to show that 5hmC changes during drought in a genomic-context-dependent manner. The findings position 5hmC as a potentially dynamic regulator of stress-responsive transcription, while also highlighting important limits around causality, detection sensitivity, and transferability across plant species.
-
Sulfachloropyridazine Research Workflows
2026-10-02
Translate DHPS inhibition into reproducible enzyme inhibition assay, antimicrobial susceptibility testing, and microbiome-aware study designs. Sulfachloropyridazine is especially useful when direct antibacterial activity must be compared with community-level and infection-model outcomes.
-
Thiazovivin: Practical ROCK Inhibitor Workflow
2026-10-01
Thiazovivin (A5506) is a ROCK inhibitor for workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, and troubleshooting; it does not establish a universal concentration or exposure schedule and is not intended for diagnostic or therapeutic use.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-10-01
This ACS Nano study systematically separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic biodistribution and cell-specific uptake. Its combination of 99mTc SPECT/CT imaging with primary liver cell experiments shows that hepatocytes and stellate cells can contribute substantially to uptake, challenging a Kupffer-cell-centered model of nanoparticle clearance.
-
AMPK–SQSTM1 Feedback in Metabolic Stress
2026-09-30
A 2024 Autophagy study identifies a double-positive feedback loop in which metabolic stress activates SQSTM1/p62, while AMPK activity reinforces SQSTM1 expression and phosphorylation. This circuit coordinates KEAP1 degradation, NRF2 activation, and lysosomal AMPK signaling, offering a mechanistic explanation for antioxidant adaptation in metabolically stressed tumor cells.